-
Several h7n9 vaccines have been declared for clinical trials in China
Time of Update: 2020-04-03
On February 7, Shanghai Institute of new development and reproduction of infectious diseases announced that their research team has successfully developed a gene vaccine against the virus h7n9, which
-
The target of HongRi pharmaceutical's merger and acquisition is mainly the exclusive varieties of traditional Chinese medicine and new drugs of category 1.1
Time of Update: 2020-04-03
On August 19, Zheng Dan, Secretary of board of HongRi Pharmaceutical (300026 SZ), said in the investigation of institutions that the company plans to consider m & A after the completion of this fixed
-
New anticancer drug: the first oral drug for macular degeneration
Time of Update: 2020-04-03
Kananji Pharmaceutical Technology (Shanghai) Co., Ltd recently announced that the company has submitted the clinical research application for wet age-related macular degeneration of CM082 new anticanc
-
Phase II clinical trial of new indication of siliquax, a new class I new drug of tailing medicine, approved
Time of Update: 2020-04-03
Phase II clinical trial application for new indication of myelodysplastic syndrome (MDS) of uropolypeptide injection, a new drug of thaling Pharmaceutical Group, has been approved by the State Food an
-
Release of 2015 Guangdong Drug Registration Annual Report
Time of Update: 2020-04-03
Lu Xianping checks the data in the laboratory at the R & D center of the headquarters of Shenzhen micro core Biotechnology Co., Ltd on June 30, Guangdong food and Drug Administration held a regular ne
-
Application for production of flupentine maleate capsule
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 2, HongRi pharmaceutical declared to produce six kinds of new chemical drugs - flupentine maleate capsules, and the d
-
CFDA uncovers the amazing black curtain of drug registration
Time of Update: 2020-04-03
Reporters found that in the "blacklist" disclosed by CFDA that night, Boji medicine (300404), a new member of gem, was involved Shanghai Pharmaceutical (601607), another A-share company, was also affe
-
Zhijun pharmaceutical's class 3 new drug oral sustained release suspension of daiyinamin will be approved soon
Time of Update: 2020-04-03
According to the public information released by the State Food and drug administration, the review status of class 3.2 new drugs of Shenzhen Zhijun pharmaceutical, a subsidiary of Sinopharm, will chan
-
Jingfeng medicine obtained erlotinib clinical approval
Time of Update: 2020-04-03
Jingfeng Pharmaceutical Co., Ltd (SZ: 000908): Announcement on the approval of clinical trials obtained by its holding subsidiary I Basic information recently, Hainan Jinrui Pharmaceutical Co., Ltd.,
-
The raw materials and tablets of aripiprazole, a new class 3.1 drug of Enhua Pharmaceutical Co., Ltd., will be inspected on site
Time of Update: 2020-04-03
On May 29, information on the website of the State Food and Drug Administration (CFDA) showed that the raw materials and tablets of aripiprazole, a class 3.1 new drug of Enhua Pharmaceutical Co., Ltd.
-
A new Chinese medicine drug X002 of Guizhou bailing Alzheimer's disease encountered obstacles in preclinical research
Time of Update: 2020-04-03
Guizhou bailing has a technical problem in the pre clinical research of class 1 Chinese medicine X002 The company is tackling the technical problem and cannot predict when it will be solved X002 is us
-
New anti ed drugs are approved for clinical research
Time of Update: 2020-04-03
Recently, the reporter learned from the Shanghai Institute of pharmaceutical research of the Chinese Academy of Sciences that the tpn729 and its tablets, a new class 1.1 drug jointly researched and de
-
Execitalopram oxalate tablets, a class 3.1 antidepressant drug of Kangenbei, was approved for production
Time of Update: 2020-04-03
According to the latest information on the website of the State Food and drug administration, acecitalopram oxalate, a 3.1 antidepressant drug of Kangenbei pharmaceutical, has been approved for produc
-
Jiangzhong pharmaceutical's new Chinese medicine for hepatitis B and AIDS is patented
Time of Update: 2020-04-03
The "one kind of traditional Chinese medicine composition and its preparation method" (Patent No.: cn201210336446.2) declared by Jiangzhong pharmaceutical has obtained the invention patent of the Stat
-
Jiangsu Wuzhong invests 250 million new research drugs with a market capacity of only 100 million
Time of Update: 2020-04-03
A clarification announcement did not dispel the market's concern about the failure of research and development of new anticancer drugs in Wuzhong, Jiangsu Province The so-called new anticancer drugs a
-
Watson biosorption tetanus new vaccine completed clinical research
Time of Update: 2020-04-03
Watson biology announced in the evening of July 7 that its wholly-owned subsidiary Yuxi Watson "adsorbed tetanus vaccine" has completed the clinical research work, and recently received the "adsorbed
-
Xinlitai class 1 new blood pressure lowering drug is approved, which is said to be beneficial to impact the medical insurance catalogue in the industry
Time of Update: 2020-04-03
Xinlitai (002294 SZ) announced on the evening of the 24th that the company's class 1 new blood pressure lowering drug alisartan ester tablet, which has attracted the market's attention, has obtained t
-
Enhua pharmaceutical's aripiprazole is expected to be approved for production within the year of on-site inspection this month
Time of Update: 2020-04-03
According to the information on July 15 on the website of the State Food and Drug Administration (CFDA), Enhua pharmaceutical's aripiprazole APIs and preparations will enter the site for inspection th
-
Patent for irinotecan hydrochloride injection and its preparation
Time of Update: 2020-04-03
Nanjing Chenggong Pharmaceutical Co., Ltd., a subsidiary of Nanjing hi tech holding company, has applied for the invention patent "a kind of irinotecan hydrochloride injection and its preparation meth
-
Clinical approval for sofadel for injection, a new drug of class 1.1 in pulo pharmaceutical
Time of Update: 2020-04-03
Puluo pharmaceutical announced on the evening of July 10 that the API sofadel declared by the company was approved for phase I clinical trial Meanwhile, the controlling shareholder affiliated company
